|
|
Drew Watson is a recognized veteran in biostatistics, machine learning, and personalized medicine. He is the founder of Nephrosant, a molecular diagnostics company focused on kidney health, and currently serves as an advisor to dozens of personalized medicine, diagnostic, and pharmaceutical development companies. He is most well known for his work in oncology, where he was instrumental in the development of Oncotype DX for breast cancer, as well as diagnostic tests for ovarian, bladder, lung, colon, and prostate cancers, leukemia, and glioblastoma.
Before his work in the diagnostics and personalized medicine fields, Drew was an advisor in quality management to hundreds of international companies under the tutelage of the renowned quality management consultant - Dr. W. Edwards Deming. Drew earned his BS in Statistics from California State University East Bay, MS in Statistical Computing from Stanford University, PhD in Biostatistics from UCLA, and MBA from Golden Gate University.
Before his work in the diagnostics and personalized medicine fields, Drew was an advisor in quality management to hundreds of international companies under the tutelage of the renowned quality management consultant - Dr. W. Edwards Deming. Drew earned his BS in Statistics from California State University East Bay, MS in Statistical Computing from Stanford University, PhD in Biostatistics from UCLA, and MBA from Golden Gate University.
